Pfizer recalled more than four million packages of Nurtec ODT Thursday due to the risk of child poisoning, according to the United States Consumer Product Safety Commission (CPSC).
Pfizer is recalling the migraine medicine because it is currently in a blister packet, which is not deemed “child resistant” and therefore poses a potential risk to children. For a package to be child resistant, it must be significantly challenging for a child under five to open it, according to CPSC.
Anyone who currently has Nurtec ODT can contact Pfizer to get a free child-resistant pouch to put the medicine in, the safety commission said.
Nurtec ODT #Recall to provide child resistant pouches to patients for storage of their medicine. Click link for details. https://t.co/B9zEvxLulC pic.twitter.com/MmCnL6DDA0
— Nurtec® ODT (rimegepant) (@NurtecODT) March 16, 2023
“The recalled prescription drugs must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA). The packaging of the products is not child resistant, posing a risk of poisoning if the contents are swallowed by young children,” CPSC said.
Pfizer is recalling 4.2 million units of the packages, which contain eight 75 mg disintegrating tablets; the Poison Prevention Safety Act (PPPA) requires this drug to be in child-resistant packaging.
“The tablets are in a non-child resistant blister card packaged in a carton that includes the name of the product, dosage strength, NDC number and expiration date,” the safety commission said.
The medication was sold in pharmacies nationwide from December 2021 through March 2023.
Consumers of the product can keep their current medication and are advised to continue to keep using it as prescribed after obtaining the child-resistant pouch, according to a statement by Nurtec. The statement also explains that there is no need to return Nurtec packages and explains that “recall” refers to any situation where a product needs repair, replacement, refund, or notice/warning.
All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact [email protected].
DONATE TO BIZPAC REVIEW
Please help us! If you are fed up with letting radical big tech execs, phony fact-checkers, tyrannical liberals and a lying mainstream media have unprecedented power over your news please consider making a donation to BPR to help us fight them. Now is the time. Truth has never been more critical!
- Southwest passenger assists plane landing after pilot has medical emergency mid-flight - March 23, 2023
- Sex abuse allegations surrounding nonprofit are ‘irrelevant,’ says Minnesota Dem looking to fund their work - March 20, 2023
- Pfizer recalls millions of pills over risk of child poisoning - March 17, 2023
We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.